Overly conservative upgrade; scope for further surprises remains open
05/08/26 -"The Q2 results exceeded expectations, aided by sustained strong uptake for the Wegovy pill (obesity). Consequently, the management upgraded its full-year guidance. Nonetheless, the extent of the ..."
Pages
65
Language
English
Published on
05/08/26
You may also be interested by these reports :
05/08/26
The Q2 results exceeded expectations, aided by sustained strong uptake for the Wegovy pill (obesity). Consequently, the management upgraded its ...
04/08/26
BioNTech reported a disappointing quarter, with sales significantly below forecasts and operating losses exceeding expectations. Weaker Covid-19 ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...
03/08/26
Astra’s media-reported merger/acquisition talks with Bristol Myers Squibb (BMS) entail worries for Astra’s shareholders – considerable overlapping ...